GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Cash Conversion Cycle
中文

Myriad Genetics (Myriad Genetics) Cash Conversion Cycle : 43.93 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Myriad Genetics's Days Sales Outstanding for the three months ended in Dec. 2023 was 53.26.
Myriad Genetics's Days Inventory for the three months ended in Dec. 2023 was 34.89.
Myriad Genetics's Days Payable for the three months ended in Dec. 2023 was 44.22.
Therefore, Myriad Genetics's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 43.93.


Myriad Genetics Cash Conversion Cycle Historical Data

The historical data trend for Myriad Genetics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cash Conversion Cycle Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.86 63.12 35.75 31.11 42.65

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.48 37.53 32.13 33.27 43.93

Competitive Comparison of Myriad Genetics's Cash Conversion Cycle

For the Diagnostics & Research subindustry, Myriad Genetics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cash Conversion Cycle falls into.



Myriad Genetics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Myriad Genetics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=52.31+32.53-42.19
=42.65

Myriad Genetics's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=53.26+34.89-44.22
=43.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics  (NAS:MYGN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Myriad Genetics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108